Loading…
Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India
Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment...
Saved in:
Published in: | The National medical journal of India 2020-09, Vol.33 (5), p.271-275 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 275 |
container_issue | 5 |
container_start_page | 271 |
container_title | The National medical journal of India |
container_volume | 33 |
creator | Pathy, Sushmita Venkatesulu, Bhanu Mallick, Supriya Deo, Suryanarayana Mohanti, Bidhu |
description | Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid.
Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome.
Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06).
Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes. |
doi_str_mv | 10.4103/0970-258X.317464 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2548416594</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A666699239</galeid><sourcerecordid>A666699239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-d7719863fd3c65428f1e33f1c756533f2e65c651e5b2f5dcff6576841d8cf9d23</originalsourceid><addsrcrecordid>eNptks9vFCEUxyfGJtbWu0cSE-NltgMMzIy3tWlrkyZeNPFGEB5dtgxsgem6_71MVu2uEQ68PD7fx4_vq6q3uFm0uKEXzdA1NWH99wXFXcvbF9Xp39TLg_hV9TqlddNwihk-rR6Xej09SZ9RlNrKbINHeQVRbnbIhIhG6ey9n_fzNIYpJhTMDCDYgbP6I7r6uYFowStAJoYRSZQhZivjDilZshEp8DkCsh7d-nLEeXVipEvw5vd6Vn27vvp6-bm--3Jze7m8q1WL21zrrsNDz6nRVHHWkt5goNRg1THOSkCAs7KBgf0ghmllDGcd71use2UGTehZ9WFfdxPD4wQpi9EmBc5JD2FKgrC20JwNbUHf_YOuy1N9ud1McUZ6MjTP1L10IKw3IUep5qJiycsYBkKHQi3-Q5WpYbQqeDC25I8E7w8EK5Aur1Jw02xFOgabPahiSCmCEZtox_LRAjdi7gExmyxmk8W-B4rk016yDa7Ykh7ctIUoRtAPPmyPdPWBTpAOiz-NQX8BZ_S3xQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546528290</pqid></control><display><type>article</type><title>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</title><source>Alma/SFX Local Collection</source><creator>Pathy, Sushmita ; Venkatesulu, Bhanu ; Mallick, Supriya ; Deo, Suryanarayana ; Mohanti, Bidhu</creator><creatorcontrib>Pathy, Sushmita ; Venkatesulu, Bhanu ; Mallick, Supriya ; Deo, Suryanarayana ; Mohanti, Bidhu</creatorcontrib><description>Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid.
Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome.
Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06).
Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.</description><identifier>ISSN: 0970-258X</identifier><identifier>EISSN: 0970-258X</identifier><identifier>DOI: 10.4103/0970-258X.317464</identifier><language>eng</language><publisher>New Delhi: Wolters Kluwer India Pvt. Ltd</publisher><subject>Cancer ; Care and treatment ; Lymphatic system ; Medical records ; Radiation ; Radiation therapy ; Radiotherapy ; Tumors</subject><ispartof>The National medical journal of India, 2020-09, Vol.33 (5), p.271-275</ispartof><rights>COPYRIGHT 2020 Medknow Publications and Media Pvt. Ltd.</rights><rights>2020. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Pathy, Sushmita</creatorcontrib><creatorcontrib>Venkatesulu, Bhanu</creatorcontrib><creatorcontrib>Mallick, Supriya</creatorcontrib><creatorcontrib>Deo, Suryanarayana</creatorcontrib><creatorcontrib>Mohanti, Bidhu</creatorcontrib><title>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</title><title>The National medical journal of India</title><description>Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid.
Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome.
Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06).
Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.</description><subject>Cancer</subject><subject>Care and treatment</subject><subject>Lymphatic system</subject><subject>Medical records</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Tumors</subject><issn>0970-258X</issn><issn>0970-258X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNptks9vFCEUxyfGJtbWu0cSE-NltgMMzIy3tWlrkyZeNPFGEB5dtgxsgem6_71MVu2uEQ68PD7fx4_vq6q3uFm0uKEXzdA1NWH99wXFXcvbF9Xp39TLg_hV9TqlddNwihk-rR6Xej09SZ9RlNrKbINHeQVRbnbIhIhG6ey9n_fzNIYpJhTMDCDYgbP6I7r6uYFowStAJoYRSZQhZivjDilZshEp8DkCsh7d-nLEeXVipEvw5vd6Vn27vvp6-bm--3Jze7m8q1WL21zrrsNDz6nRVHHWkt5goNRg1THOSkCAs7KBgf0ghmllDGcd71use2UGTehZ9WFfdxPD4wQpi9EmBc5JD2FKgrC20JwNbUHf_YOuy1N9ud1McUZ6MjTP1L10IKw3IUep5qJiycsYBkKHQi3-Q5WpYbQqeDC25I8E7w8EK5Aur1Jw02xFOgabPahiSCmCEZtox_LRAjdi7gExmyxmk8W-B4rk016yDa7Ykh7ctIUoRtAPPmyPdPWBTpAOiz-NQX8BZ_S3xQ</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Pathy, Sushmita</creator><creator>Venkatesulu, Bhanu</creator><creator>Mallick, Supriya</creator><creator>Deo, Suryanarayana</creator><creator>Mohanti, Bidhu</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Scientific Scholar</general><scope>AAYXX</scope><scope>CITATION</scope><scope>04Q</scope><scope>04T</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</title><author>Pathy, Sushmita ; Venkatesulu, Bhanu ; Mallick, Supriya ; Deo, Suryanarayana ; Mohanti, Bidhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-d7719863fd3c65428f1e33f1c756533f2e65c651e5b2f5dcff6576841d8cf9d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cancer</topic><topic>Care and treatment</topic><topic>Lymphatic system</topic><topic>Medical records</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pathy, Sushmita</creatorcontrib><creatorcontrib>Venkatesulu, Bhanu</creatorcontrib><creatorcontrib>Mallick, Supriya</creatorcontrib><creatorcontrib>Deo, Suryanarayana</creatorcontrib><creatorcontrib>Mohanti, Bidhu</creatorcontrib><collection>CrossRef</collection><collection>India Database</collection><collection>India Database: Health & Medicine</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>The National medical journal of India</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pathy, Sushmita</au><au>Venkatesulu, Bhanu</au><au>Mallick, Supriya</au><au>Deo, Suryanarayana</au><au>Mohanti, Bidhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India</atitle><jtitle>The National medical journal of India</jtitle><date>2020-09-01</date><risdate>2020</risdate><volume>33</volume><issue>5</issue><spage>271</spage><epage>275</epage><pages>271-275</pages><issn>0970-258X</issn><eissn>0970-258X</eissn><abstract>Background. Tumours of the eyelid are a rare subgroup of neoplasms with varied histology and inherent differences in clinical behaviour. Surgery is the standard of care, and adjuvant radiation therapy (RT) is given in the presence of features suggesting a high risk of local recurrence. The treatment of lymph nodes in the neck is debatable. We reviewed the utility of RT for lymph nodes in the neck in patients with malignant tumours of the eyelid.
Methods. We reviewed medical records of all patients with tumours of the eyelid treated at our centre from July 2006 to December 2014 for their demographic, clinical profile, treatment details and outcome.
Results. The records of 37 patients were included for analysis, of these 34 underwent surgery and 21 received adjuvant RT. Their median age was 60 (range 30-85) years. Sebaceous cell carcinoma was the most common (50.4%). The median disease-free survival (DFS) was 35 months (95% CI 17.9-52.0). The 1- and 3-year DFS were 82.7% and 45%, respectively. Univariate analysis showed a superior outcome with early stage (T1) tumours (p=0.01), RT dose of ≥60 Gy and those underwent lymph node dissection (p=0.03). The presence of high-risk factors including close or positive margin had an inferior outcome with a trend towards statistical significance (p=0.06).
Conclusion. We found a favourable outcome with early T stage, RT dose of ≥60 Gy and lymph node dissection. High-risk histopathological features including close margins and positive lymph nodes merit adjuvant RT including regional lymph nodes.</abstract><cop>New Delhi</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/0970-258X.317464</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0970-258X |
ispartof | The National medical journal of India, 2020-09, Vol.33 (5), p.271-275 |
issn | 0970-258X 0970-258X |
language | eng |
recordid | cdi_proquest_miscellaneous_2548416594 |
source | Alma/SFX Local Collection |
subjects | Cancer Care and treatment Lymphatic system Medical records Radiation Radiation therapy Radiotherapy Tumors |
title | Adjuvant radiation therapy for malignant tumours of the eyelid: Experience from a tertiary cancer centre in India |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A24%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20radiation%20therapy%20for%20malignant%20tumours%20of%20the%20eyelid:%20Experience%20from%20a%20tertiary%20cancer%20centre%20in%20India&rft.jtitle=The%20National%20medical%20journal%20of%20India&rft.au=Pathy,%20Sushmita&rft.date=2020-09-01&rft.volume=33&rft.issue=5&rft.spage=271&rft.epage=275&rft.pages=271-275&rft.issn=0970-258X&rft.eissn=0970-258X&rft_id=info:doi/10.4103/0970-258X.317464&rft_dat=%3Cgale_proqu%3EA666699239%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c414t-d7719863fd3c65428f1e33f1c756533f2e65c651e5b2f5dcff6576841d8cf9d23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2546528290&rft_id=info:pmid/&rft_galeid=A666699239&rfr_iscdi=true |